General introduction and thesis outline 29 67. Raaymakers BW, Jurgenliemk-Schulz IM, Bol GH, Glitzner M, Kotte ANTJ, van Asselen B, et al. First patients treated with a 1.5 T MRI-Linac: clinical proof of concept of a high-precision, high-field MRI guided radiotherapy treatment. Phys Med Biol 2017;62:L41– 50. 68. Maspero M, Savenije MHF, Dinkla AM, Seevinck PR, Intven MPW, Ina M, et al. Dose evaluation of fast synthetic-CT generation using a generative adversarial network for general pelvis MR-only radiotherapy 2018. Phys Med Biol 2018;63:1–17. 69. Kerkmeijer LGW, Maspero M, Meijer GJ, van der Voort van Zyp JRN, de Boer HCJ, van den Berg CAT. Magnetic Resonance Imaging only Workflow for Radiotherapy Simulation and Planning in Prostate Cancer. Clin Oncol (R Coll Radiol) 2018;30:692–701. 70. Winkel D, Bol GH, Kroon PS, van Asselen B, Hackett SS, Werensteijn-Honingh AM, et al. Adaptive radiotherapy: The Elekta Unity MR-linac concept. Clin Transl Radiat Oncol 2019;18:54–9. 71. de Muinck Keizer DM, van der Voort van Zyp JRN, de Groot-van Breugel EN, Raaymakers BW, Lagendijk JJW, de Boer HCJ. On-line daily plan optimization combined with a virtual couch shift procedure to address intrafraction motion in prostate magnetic resonance guided radiotherapy. Phys Imaging Radiat Oncol 2021;19:90–5. 72. de Mol van Otterloo SR, Christodouleas JP, Blezer ELA, Akhiat H, Brown K, Choudhury A, et al. The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy. Front Oncol 2020;10:1328. 73. Zumsteg ZS, Spratt DE, Romesser PB, Pei X, Zhang Z, Polkinghorn W, et al. The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy. Eur Urol 2015;67:1009–16. 74. Punnen S, Cooperberg MR, D’Amico A V, Karakiewicz PI, Moul JW, Scher HI, et al. Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol 2013;64:905–15. 75. Zumsteg ZS, Spratt DE, Romesser PB, Pei X, Zhang Z, Kollmeier M, et al. Anatomic Patterns of Recurrence Following Biochemical Relapse in the DoseEscalation Era for Prostate Patients Undergoing External Beam Radiotherapy. J Urol 2015;194:1624– 30. 76. Tran H, Kwok J, Pickles T, Tyldesley S, Black PC. Underutilization of local salvage therapy after radiation therapy for prostate cancer. Urol Oncol 2014;32:701–6. 77. Nguyen PL, Alibhai SMH, Basaria S, D’Amico A V, Kantoff PW, Keating NL, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 2015;67:825–36. 78. Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin M-E, Ryan CW, et al. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormonerefractory prostate cancer who are refractory to docetaxel. Cancer 2008;112:521–6. 79. James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, et al. Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol 2015;67:1028–38. 80. Gravis G, Boher J-M, Joly F, Soulié M, Albiges L, Priou F, et al. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. Eur Urol 2016;70:256–62. 81. Steele EM, Holmes JA. A review of salvage treatment options for disease progression after radiation therapy for localised prostate cancer. Urol Oncol Semin Orig Investig 2019;37:582–98. 82. Van Son M, Peters M, Moerland M, Kerkmeijer L, Lagendijk J, Van der Voort van Zyp J. Focal salvage treatment of radiorecurrent prostate cancer: A narrative review of current strategies and future perspectives. Cancers 2018;10:480. 83. Corkum MT, Mendez LC, Chin J, D’Souza D, Boldt RG, Bauman GS. A Novel Salvage Option for Local Failure in Prostate Cancer, Reirradiation Using External Beam or Stereotactic Radiation Therapy: Systematic Review and Meta-Analysis. Adv Radiat Oncol 2020;5:965–77. 84. Valle LF, Lehrer EJ, Markovic D, Elashoff D, LevinEpstein R, Karnes RJ, et al. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). Eur Urol 2020. 85. Hostiou T, Gelet A, Chapelon J-Y, Rouvière O, MègeLechevalier F, Lafon C, et al. Salvage high-intensity focused ultrasound for locally recurrent prostate cancer after low-dose-rate brachytherapy: oncological and functional outcomes. BJU Int 2019;124:746–57. 86. Zilli T, Benz E, Dipasquale G, Rouzaud M, Miralbell R. Reirradiation of Prostate Cancer Local Failures After Previous Curative Radiation Therapy: Long-Term Outcome and Tolerance. Int J Radiat Oncol Biol Phys 2016;96:318–22. 1
RkJQdWJsaXNoZXIy MTk4NDMw